This is a working overview of reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-29 and is reviewed periodically as new material appears.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Lyophilized material is generally held at reduced temperature to slow degradation, and storage at minus twenty degrees Celsius or lower is common practice for long-term retention. Short-term working portions are often kept between two and eight degrees Celsius. Once dissolved, the peptide is less stable than the dry powder, and repeated freeze-thaw cycles are associated with loss of material and with aggregate formation. Vials are usually allowed to reach room temperature before opening so that condensation does not introduce moisture, and solutions are protected from light where practical.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography, which separates the peptide from closely related impurities and from truncated or oxidized variants. Mass spectrometry supplies the molecular mass and confirms the expected sequence length, while amino acid analysis can be used to check composition. Because the molecule has no chromophore beyond the peptide backbone, ultraviolet detection is typically performed at a low wavelength, where baseline interference from solvents and buffers is a practical concern. Water content and counter-ion content are often reported alongside purity.
xanthosine 5'-phosphate + NADH + H+ The mechanism of IMPDH involves a sequence of two different chemical reactions: (1) a fast redox reaction involving a hydride transfer to NAD+ which generates NADH and an enzyme-bound XMP intermediate (E-XMP*) and (2) a hydrolysis step that releases XMP from the enzyme. IMP binds to the active site and a conserved cysteine residue attacks the 2-position of the purine ring. A hydride ion is then transferred from the C2 position to NAD+ and the E-XMP* intermediate is formed. NADH dissociates from the enzyme and a mobile active-site flap element moves a conserved catalytic dyad of arginine and threonine into the newly unoccupied NAD binding site. The arginine residue is thought to act as the general base that activates a water molecule for the hydrolysis reaction. Alternatively, molecular mechanics simulations suggest that in conditions where the arginine residue is protonated, the threonine residue is also capable of activating water by accepting a proton from water while transferring its own proton to a nearby residue.
IBA Lifesciences is a biotechnology company providing products and custom specific services for life science applications in academia and industry worldwide. IBA focusses on two business segments: cell selection and protein purification. The company is the original manufacturer and supplier of the Strep-tag/Strep-Tactin technology, an affinity chromatography system developed for protein purification. The method is based on one of the strongest non-covalent interactions in nature, which is the interaction of biotin to streptavidin. An intrinsic binding affinity of the Strep-tag towards Strep-Tactin results in a highly specific interaction, which enables the isolation and purification of sensitive proteins in a native state as wells as intact protein complexes, respectively. The technology was patented by the Max Planck Society (former “Garching Innovations”) and later assigned to IBA. Recently, the method was further developed to be used for cell selection from whole blood or other single cell suspensions.
can replace separate correlations for individual properties. Conversely, a variety of experimental measurements (e.g., density, heat capacity, vapor pressure) can be incorporated into the same fit; in principle, this would allow one to predict hard-to-measure properties like heat capacity in terms of other, more readily available measurements (e.g., vapor pressure).
The conformational mobility of serpins provides a key advantage over static lock-and-key protease inhibitors. In particular, the function of inhibitory serpins can be regulated by allosteric interactions with specific cofactors. The X-ray crystal structures of antithrombin, heparin cofactor II, MENT and murine antichymotrypsin reveal that these serpins adopt a conformation wherein the first two amino acids of the RCL are inserted into the top of the A β-sheet. The partially inserted conformation is important because co-factors are able to conformationally switch certain partially inserted serpins into a fully expelled form. This conformational rearrangement makes the serpin a more effective inhibitor. The archetypal example of this situation is antithrombin, which circulates in plasma in a partially inserted relatively inactive state. The primary specificity determining residue (the P1 arginine) points toward the body of the serpin and is unavailable to the protease. Upon binding a high-affinity pentasaccharide sequence within long-chain heparin, antithrombin undergoes a conformational change, RCL expulsion, and exposure of the P1 arginine. The heparin pentasaccharide-bound form of antithrombin is, thus, a more effective inhibitor of thrombin and factor Xa. Furthermore, both of these coagulation proteases also contain binding sites (called exosites) for heparin. Heparin, therefore, also acts as a template for binding of both protease and serpin, further dramatically accelerating the interaction between the two parties.
Sources: en.wikipedia.org
== Contraindications == Quinolones are not recommended in people with epilepsy, Marfan's syndrome, Ehlers–Danlos syndrome, QT prolongation, pre-existing CNS lesions, or CNS inflammation, or who have had a stroke. They are best avoided in the athlete population. Safety concerns exist for fluoroquinolone use during pregnancy, so they are contraindicated unless no other safe alternative antibiotic exists. However, one meta-analysis looking at the outcome of pregnancies involving quinolone use in the first trimester found no increased risk of malformations. They are also contraindicated in children due to the risks of damage to the musculoskeletal system. Their use in children is not absolutely contraindicated, however for certain severe infections where other antibiotics are not an option, their use can be justified. Quinolones should also not be given to people with a known hypersensitivity to the drug class. The basic pharmacophore, or active structure, of the fluoroquinolone class is based upon the quinoline ring system. The addition of the fluorine atom at C6 distinguishes the successive-generation fluoroquinolones from the first-generation of quinolones. The addition of the C6 fluorine atom has since been demonstrated not to be required for the antibacterial activity of this class (circa 1997).
Cordelia, afraid that her brother might tell him of James' grandfather, eavesdrops on her brother and Charles' conversation and finds out that Alastair and Charles are gay and Charles was marrying Ariadne for power only. He was scared of rejection by the society and hence couldn't publicly display his sexual orientation. The next morning, James visits Cordelia and they, along with Matthew and Lucie pay a visit to Emmanuel Gast. However, he is already dead. Lucie summons his ghost and learns that he had raised the demon who was wreaking havoc over London. He claimed that he knew her grandfather, but she banished him before he could reveal much. Later they find splinters of wood with strange inscriptions. The four head back to the institute. Charles arrives in a carriage, bringing Grace and a bloodied Tatiana to the Institute. Once Tatiana is being treated in their infirmary, Grace pulls James aside to talk to him. James takes Grace aside where she informs him that she is now engaged to Charles - who had broken off his engagement with Ariadne whilst she was unconscious. Grace demands her bracelet back from him and when he returns it, he feels physical pain from the separation. He goes to the Blackfriars Bridge to relieve his heartache. Grace finds Matthew and tells him what has transpired. Before she leaves, she seemingly holds Matthew in place with words alone and kisses him. She threatens to tell James about this kiss if Matthew ever breathes a word of their conversation to anyone.
Betadine products and medical variants by Avrio Health (part of Purdue Pharma) Ingredients: Povidon-iodine etc. As of June 2021, not recommended by manufacturer to "kill" coronaviruses. Bleach products: Clorox Cyosan Zonrox Bleach Henkel products: biff Hygiene Total Ingredients: Benzalkonium chloride and formic acid Tested against SARS-CoV-2 according to producer statement on website. Bref Power Bakterien & Schimmel Purex Heitmann Hygiene & Care products: Universal Hygiene Laundry Rinse 1.5 Ingredients: Didecyldimethylammonium chloride Hygiene Spray Ingredients: Ethanol, 2-propanol According to manufacturer is effective against coronaviruses, including SARS-CoV-2 Listerine Ingredients: Alcohol, sodium fluoride, essential oils (specifically in case of management of inflammatory periodontal diseases) Unknown or limited virucidal activity Lysol Ingredient: Benzalkonium chloride Some of the products having been tested against SARS-CoV-2. Sterillium Ingredients: 1-Propanol, 2-propanol and mecetronium ethylsulfate By former Bode Chemie, now Hartmann AG, one of Germany's major health-care brands available in 50 countries, and according to website "the world's most scientifically researched hand disinfectant with approximately 60 scientific publications in trade journals in 2015."
=== Type II Diabetes === Patients with Type II diabetes will have elevated glucagon levels during a fast and after eating. These elevated glucagon levels over stimulate the liver to undergo gluconeogenesis, leading to elevated blood glucose levels. Consistently high blood glucose levels can lead to organ damage, neuropathy, blindness, cardiovascular issues and bone and joint problems. It is not entirely clear why glucagon levels are so high in patients with Type II diabetes. One theory is that the alpha cells have become resistant to the inhibitory effects of glucose and insulin and do not respond properly to them. Another theory is that nutrient stimulation of the gastrointestinal tract, thus the secretion of gastric inhibitory polypeptide and Glucagon-like peptide-1, is a very important factor in the elevated secretion of glucagon.
Meinhard I 1253–1258, also Count of Gorizia since 1231 Meinhard II 1258–1295, also Count of Gorizia until 1271, Duke of Carinthia and Margrave of Carniola from 1286, jointly with: Albert V 1258–1271, brother, also Count of Gorizia until 1304 Albert VI, son, until 1292 Henry II 1295–1335, son of Meinhard II, also Duke of Carinthia, King of Bohemia 1306 and 1307–1310, jointly with his brothers Louis, until 1305 Otto, until 1310 Male line extinct, Countess Margaret, daughter of Henry II, married to:
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Reverse-phase HPLC with ultraviolet detection at 214 nm is common. Mass spectrometry is used to confirm molecular identity and detect modifications. Immunoassays exist but may not distinguish the intact peptide from fragments.